Disc Medicine Showcases Clinical Progress at EHA Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: NASDAQ.COM
- RALLY-MF Trial Results: In the Phase 2 RALLY-MF trial, over 55% of non-transfusion dependent patients achieved a major hemoglobin response within 12 weeks, demonstrating the efficacy of DISC-0974 in treating myelofibrosis and enhancing the company's competitive edge in hematological disorders.
- Transfusion Independence Improvement: Among transfusion-dependent patients, 64% with low burden and 50% with high burden achieved transfusion independence, indicating significant potential for improving patient quality of life and possibly advancing further clinical development.
- HELIOS Trial Outcomes: The HELIOS extension trial showed sustained reductions in protoporphyrin IX (PPIX) and significant improvements in light tolerance for patients on continuous 60 mg dosing over 2.5 years, indicating long-term safety and efficacy of Bitopertin in treating erythropoietic protoporphyria.
- Upcoming Milestones: Disc expects to engage in end-of-Phase 2 discussions with the FDA for DISC-0974 by year-end and to report Phase 3 APOLLO trial results for Bitopertin in Q4 2026, potentially paving the way for traditional approval and furthering the company's strategic positioning in hematological therapies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 70.210
Low
100.00
Averages
120.20
High
154.00
Current: 70.210
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing materially misleading business information, allowing affected investors to seek compensation without upfront costs.
- FDA Response Letter: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in their new drug application prevented approval, resulting in a 22% stock price drop on the same day, highlighting significant regulatory challenges.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, encouraging investors to join through their website or toll-free number, which underscores their commitment to safeguarding investor rights amid potential corporate misconduct.
- Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in the legal landscape for investor protection.
See More
Goldman Sachs and Broadcom Options Trading Volume Surge
- Goldman Sachs Options Volume: As of today, Goldman Sachs options volume reached 33,776 contracts, equivalent to approximately 3.4 million shares, representing a significant 143.3% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- Specific Goldman Sachs Options: Among Goldman Sachs options, the $1300 strike call option expiring on July 17, 2026, has seen 3,174 contracts traded today, representing about 317,400 underlying shares, reflecting investor enthusiasm for this price level.
- Broadcom Options Volume: Broadcom's options also show robust activity, with a total of 434,977 contracts traded, equivalent to approximately 43.5 million shares, which is 132.2% of its average daily trading volume over the past month, suggesting continued market confidence in Broadcom.
- Specific Broadcom Options: For Broadcom, the $400 strike call option expiring on June 17, 2026, has recorded a trading volume of 26,180 contracts today, representing around 2.6 million underlying shares, indicating bullish expectations from investors at this price point.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing misleading business information, indicating legal risks that could impact shareholder returns.
- FDA Response Letter: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties requiring additional evidence, which led to a 22% drop in the company's stock price on the same day, reflecting market concerns about its product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing affected investors to seek compensation without any out-of-pocket fees, potentially providing legal support to help recover losses.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in securities litigation, which investors should consider when selecting legal counsel.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ:IRON) due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- FDA Response Letter Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application, which caused the company's stock price to plummet 22% on the same day, reflecting market concerns about its product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to participate without any out-of-pocket fees, aiming to recover losses incurred due to the company's misleading information.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Disc Medicine Showcases Clinical Progress at EHA Annual Meeting
- RALLY-MF Trial Results: In the Phase 2 RALLY-MF trial, over 55% of non-transfusion dependent patients achieved a major hemoglobin response within 12 weeks, demonstrating the efficacy of DISC-0974 in treating myelofibrosis and enhancing the company's competitive edge in hematological disorders.
- Transfusion Independence Improvement: Among transfusion-dependent patients, 64% with low burden and 50% with high burden achieved transfusion independence, indicating significant potential for improving patient quality of life and possibly advancing further clinical development.
- HELIOS Trial Outcomes: The HELIOS extension trial showed sustained reductions in protoporphyrin IX (PPIX) and significant improvements in light tolerance for patients on continuous 60 mg dosing over 2.5 years, indicating long-term safety and efficacy of Bitopertin in treating erythropoietic protoporphyria.
- Upcoming Milestones: Disc expects to engage in end-of-Phase 2 discussions with the FDA for DISC-0974 by year-end and to report Phase 3 APOLLO trial results for Bitopertin in Q4 2026, potentially paving the way for traditional approval and furthering the company's strategic positioning in hematological therapies.
See More
Updated Clinical Data on DISC-0974 and Bitopertin
- RALLY-MF Trial Results: In the RALLY-MF trial, DISC-0974 demonstrated significant anemia responses in 61 patients with myelofibrosis (MF) and anemia, with 55% of non-transfusion dependent patients achieving a hemoglobin increase of ≥1.5 g/dL within 12 weeks, indicating the drug's potential to improve patient quality of life.
- HELIOS Trial Update: The HELIOS trial showed that patients treated with bitopertin experienced sustained reductions in PPIX levels and significant improvements in light tolerance, highlighting the long-term safety and efficacy of the drug in treating erythropoietic protoporphyria (EPP).
- Future Development Plans: Disc Medicine plans to share initial data from DISC-3405 in patients with polycythemia vera in Q4 2026, marking the company's ongoing innovation and potential market expansion in hematologic disease treatments.
- Management Conference Call: The company will host a conference call on June 15 to review highlights of the data presented at the EHA meeting and outline next steps, further enhancing investor confidence in the company's future growth.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) for allegedly issuing materially misleading business information, allowing affected investors to seek compensation without upfront costs.
- FDA Response Letter: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in their new drug application prevented approval, resulting in a 22% stock price drop on the same day, highlighting significant regulatory challenges.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, encouraging investors to join through their website or toll-free number, which underscores their commitment to safeguarding investor rights amid potential corporate misconduct.
- Firm's Reputation: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in the legal landscape for investor protection.
See More
Goldman Sachs and Broadcom Options Trading Volume Surge
- Goldman Sachs Options Volume: As of today, Goldman Sachs options volume reached 33,776 contracts, equivalent to approximately 3.4 million shares, representing a significant 143.3% of its average daily trading volume over the past month, indicating strong market interest in its future performance.
- Specific Goldman Sachs Options: Among Goldman Sachs options, the $1300 strike call option expiring on July 17, 2026, has seen 3,174 contracts traded today, representing about 317,400 underlying shares, reflecting investor enthusiasm for this price level.
- Broadcom Options Volume: Broadcom's options also show robust activity, with a total of 434,977 contracts traded, equivalent to approximately 43.5 million shares, which is 132.2% of its average daily trading volume over the past month, suggesting continued market confidence in Broadcom.
- Specific Broadcom Options: For Broadcom, the $400 strike call option expiring on June 17, 2026, has recorded a trading volume of 26,180 contracts today, representing around 2.6 million underlying shares, indicating bullish expectations from investors at this price point.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON) for allegedly issuing misleading business information, indicating legal risks that could impact shareholder returns.
- FDA Response Letter: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties requiring additional evidence, which led to a 22% drop in the company's stock price on the same day, reflecting market concerns about its product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing affected investors to seek compensation without any out-of-pocket fees, potentially providing legal support to help recover losses.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in securities litigation, which investors should consider when selecting legal counsel.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ:IRON) due to allegations of misleading business information, aiming to protect investor rights and seek compensation.
- FDA Response Letter Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application, which caused the company's stock price to plummet 22% on the same day, reflecting market concerns about its product prospects.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit, allowing investors to participate without any out-of-pocket fees, aiming to recover losses incurred due to the company's misleading information.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Disc Medicine Showcases Clinical Progress at EHA Annual Meeting
- RALLY-MF Trial Results: In the Phase 2 RALLY-MF trial, over 55% of non-transfusion dependent patients achieved a major hemoglobin response within 12 weeks, demonstrating the efficacy of DISC-0974 in treating myelofibrosis and enhancing the company's competitive edge in hematological disorders.
- Transfusion Independence Improvement: Among transfusion-dependent patients, 64% with low burden and 50% with high burden achieved transfusion independence, indicating significant potential for improving patient quality of life and possibly advancing further clinical development.
- HELIOS Trial Outcomes: The HELIOS extension trial showed sustained reductions in protoporphyrin IX (PPIX) and significant improvements in light tolerance for patients on continuous 60 mg dosing over 2.5 years, indicating long-term safety and efficacy of Bitopertin in treating erythropoietic protoporphyria.
- Upcoming Milestones: Disc expects to engage in end-of-Phase 2 discussions with the FDA for DISC-0974 by year-end and to report Phase 3 APOLLO trial results for Bitopertin in Q4 2026, potentially paving the way for traditional approval and furthering the company's strategic positioning in hematological therapies.
See More
Updated Clinical Data on DISC-0974 and Bitopertin
- RALLY-MF Trial Results: In the RALLY-MF trial, DISC-0974 demonstrated significant anemia responses in 61 patients with myelofibrosis (MF) and anemia, with 55% of non-transfusion dependent patients achieving a hemoglobin increase of ≥1.5 g/dL within 12 weeks, indicating the drug's potential to improve patient quality of life.
- HELIOS Trial Update: The HELIOS trial showed that patients treated with bitopertin experienced sustained reductions in PPIX levels and significant improvements in light tolerance, highlighting the long-term safety and efficacy of the drug in treating erythropoietic protoporphyria (EPP).
- Future Development Plans: Disc Medicine plans to share initial data from DISC-3405 in patients with polycythemia vera in Q4 2026, marking the company's ongoing innovation and potential market expansion in hematologic disease treatments.
- Management Conference Call: The company will host a conference call on June 15 to review highlights of the data presented at the EHA meeting and outline next steps, further enhancing investor confidence in the company's future growth.
See More
